The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How should molecular profiling be used to guide MDS therapy?

During the Acute Leukemia Forum (ALF) 2021, the MDS Hub spoke to Rafael Bejar, UC San Diego, San Diego, US. We asked, How should molecular profiling be used to guide MDS therapy?

How should molecular profiling be used to guide MDS therapy?

It is well understood that MDS is caused by somatic mutations in blood cells, influencing a patient's clinical presentation. In this video, Bejar discusses how DNA sequencing can help determine the diagnosis, prognosis, and identify targeted therapy options for patients with a wide variety of MDS risk features and gene mutations.

 

Share: